On February 21, 2020, Chen, Xiangyang; Pang, Yucheng published a patent.Synthetic Route of 29704-38-9 The title of the patent was Pyridazine-3-carboxamide compound, its preparation and application in medicine. And the patent contained the following:
The invention relates to pyridazine-3-carboxamide compound of formula I as Janus Kinase inhibitor, its preparation and application for treatment of Janus Kinase-mediated diseases. Compounds I, wherein Z is N or CR1; ring A is substituted C6-10 aromatic ring or 5-10-membered aromatic hetero-ring; L is a bond or substituted C1-6 alkylene; R is H, halogen, cyano, SF5, etc.; R1 is H, halo, CN, etc.; Ra, Rb, Rc , Rd and Re are independently H, halo, CN, etc.; their pharmaceutically acceptable salts, prodrug, isomers or mixtures, are claimed. The inventive compound is capable of inhibiting or controlling Janus kinase, especially tyrosine kinase 2, and can be applied to the prevention and treatment of Janus kinase-mediated diseases, especially autoimmune disease, inflammatory disease and cancer. The experimental process involved the reaction of tert-Butyl 2-(4-nitrophenyl)acetate(cas: 29704-38-9).Synthetic Route of 29704-38-9
The Article related to pyridazine carboxamide preparation janus kinase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Synthetic Route of 29704-38-9
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics